CardiALLO is under clinical development by BioCardia and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CardiALLO’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CardiALLO overview

CardiALLO is under development for the treatment of ischemic systolic heart failure. The therapeutic candidate comprises of culture-expanded, bone marrow-derived, allogeneic neurokinin-1 receptor positive (NK1R+) mesenchymal stem cells from a universal donor and it is delivered with the helix transendocardial delivery system. It was also under development for the treatment of sub acute myocardial infraction, coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).. It is administered through intravenous route.

BioCardia overview

BioCardia is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, autologous minimally processed bone marrow cells and an allogeneic off-the-shelf mesenchymal stem a cell product candidate for ischemic systolic heart failure. BioCardia‘s CardiAMP cell therapy system comprises a cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US

For a complete picture of CardiALLO’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.